|drug3769||blood tests Wiki||1.00|
|drug2154||Nasopharyngeal swabs Wiki||0.71|
|D001172||Arthritis, Rheumatoid NIH||0.30|
There is one clinical trial.
The COVID-19 pandemic is of grave concern due its impact on human health and on the economy. Propolis, a natural resin produced by bees from plant materials, has anti-inflammatory, immunomodulatory, anti-oxidant properties, and various aspects of the SARS-CoV-2 infection mechanism are potential targets for propolis compounds. Propolis components have inhibitory effects on the ACE2, TMPRSS2 and PAK1 signaling pathways; in addition, antiviral activity has been proven in vitro and in vivo. This is a pilot randomized study that aims to assess the impact of using Brazilian green propolis extract against the deleterious effects of the new coronavirus.
Description: Composite clinical outcome with oxygen therapy dependency time (in days) or hospitalization time (in days) after randomization.Measure: Composite clinical outcome with oxygen therapy dependency time or hospitalization time Time: 1-28 days
Description: We will evaluate the presence or absence of symptoms related to the use of propolis through a questionnaire.Measure: Percentage of participants with adverse events during the use of propolis Time: 1-28 days
Description: Assess the degree of acute kidney injury according to KDIGO (through serum creatinine or urine output).Measure: Rate and severity of acute kidney injury during the study Time: 1-28 days
Description: Assess need or not for renal replacement therapy.Measure: Renal replacement therapy. Time: 1-28 days
Description: Describe the time needed for vasopressors in days after randomizationMeasure: Rate of need for vasopressor use Time: 1-28 days
Description: Assess length of stay in the ICU after randomization in daysMeasure: Need for intensive care unit (ICU) Time: 1-28 days
Description: Rate of readmission to the ICU after randomizationMeasure: Intensive care unit (ICU) readmission Time: 1-28 days
Description: Assess the need for mechanical ventilation in days after randomization.Measure: Invasive oxygenation time Time: 1-28 days
Description: Evaluate the variation in serum levels of c-reactive protein over the 7 days after randomizationMeasure: Variation of plasma c-reactive protein Time: 1-7 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports